Povorcitinib phosphate

• CAT Number: I043572
• CAS Number: 1637677-33-8
• Molecular Formula: C23H25F5N7O5P
• Molecular Weight: 605.45
• Purity: ≥95%
• Synonyms: 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide;phosphoric acid
• InChI: InChI=1S/C23H22F5N7O.H3O4P/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28;1-5(2,3)4/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33);(H3,1,2,3,4)/t14-;/m0./s1
• InChIKey: XUQIWHXYCLHHCN-UQKRIMTDSA-N
• SMILES: CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)N[C@@H](C)C(F)(F)F)F)CC#N.OP(=O)(O)O

Povorcitinib phosphate（Cat No.:I043572）is a selective oral inhibitor of Janus kinase 1 (JAK1), a key enzyme involved in the signaling pathways of various inflammatory and immune-related diseases. By inhibiting JAK1, povorcitinib phosphate modulates immune responses and reduces inflammation, making it a promising candidate for treating conditions such as rheumatoid arthritis, psoriasis, and other autoimmune disorders. Its ability to selectively target JAK1 minimizes off-target effects, offering a more targeted approach to treatment. Povorcitinib phosphate is under investigation for its therapeutic potential in managing chronic inflammatory diseases and improving patient outcomes.